Drugs / Alferminogene tadenovec
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01550614 | Mar 2012 → May 2016 | intermediate coronary syndrome | Cardium Therapeutics | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alferminogene tadenovec | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01550614 ↗ |
| Known as | Ad5FGF4 | “Evaluation of ASPIRE trial: a Phase III pivotal registration trial, using intracoronary administration of Generx (Ad5FGF4) to treat patients with recurrent angina pectoris.” PMID 23957658 ↗ Aug 20131“One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)” NCT01550614 ↗ |
| Route | Other | “One-time intracoronary infusion of Ad5FGF-4” NCT01550614 ↗ |
| Target | FGF4 | “Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer” NCT01550614 ↗ |